Effects of intrastriatal injections of glutamate receptor antagonists on the severity of paroxysmal dystonia in the dtsz mutant

被引:15
作者
Sander, Svenja Esther [1 ]
Richter, Angelika [1 ]
机构
[1] Free Univ Berlin, Inst Pharmacol & Toxicol, Dept Vet Med, D-14195 Berlin, Germany
关键词
basal ganglia; dyskinesia; glutamate; movement disorder; striatum;
D O I
10.1016/j.ejphar.2007.01.067
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Imbalances of the glutamatergic system are implicated in the pathophysiology of various basal ganglia disorders, but few is known about their role in dystonia, a common neurological syndrome in which involuntary muscle co-contractions lead to twisting movements and abnormal postures. Previous systemic administrations of glutamte receptor antagonists in dt(sz) hamsters, an animal model of primary paroxysmal dystonia, exerted antidystonic effects and electrophysiological experiments pointed to an enhanced corticostriatal glutamatergic activity. In order to examine the pathophysiological relevance of these findings, we performed striatal microiniections of the alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-soxazolepropanoic acid (AMPA) receptor antagonist 2,3-dioxo-6-nitro-7-sulfamoylbenzo(oquinoxaline (NBQX) and the N-methyl-D-aspartate (NMDA) receptor antagonists D(-)-2-amino-5-phosphopentanoic acid (AP-5), (R)-(+)-3 -amino-1-hydroxypyrrolidin-2-one (HA-966) and dizocilpine (MK-801). The striatal application of NBQX reduced the severity and increased the latency to onset of dystonia significantly only at a dosage of 0.08 mu g per hemisphere, lower (0.03 mu g) and higher dosages (0. 16 mu g and 0.32 mu g) failed to exert comparable effects on the severity. None of the striatal injected NMDA receptor antagonists influenced the severity of the dystonic attacks in the mutant hamster. The combined application of NBQX (0.08 mu g) with AP-5 (1.0 mu g) failed to exert synergistic antidystonic effects, but the beneficial effect on the severity of dystonia of the single application of NBQX was reproduced. Therefore, corticostriatal glutamatergic overactivity mediated by AMPA receptors, but not by NMDA receptors, is possibly important for the manifestation of dystonic attacks in the dt(sz) hamster mutant. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:102 / 108
页数:7
相关论文
共 34 条
[1]   Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: co-localization at synapses with the GluR2/3 subunit of the AMPA receptor [J].
Bernard, V ;
Bolam, JP .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1998, 10 (12) :3721-3736
[2]   The corticostriatal projection: From synaptic plasticity to dysfunctions of the basal ganglia [J].
Calabresi, P ;
Pisani, A ;
Mercuri, NB ;
Bernardi, G .
TRENDS IN NEUROSCIENCES, 1996, 19 (01) :19-24
[3]   Differential expression of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate glutamate receptors in the rat striatum during postnatal development [J].
Chan, WS ;
Yeung, CW ;
Chung, EKY ;
Lau, WK ;
Chan, YS ;
Yung, KKL .
NEUROSIGNALS, 2003, 12 (06) :302-309
[4]   Functional anatomy of movement disorders [J].
Crossman, AR .
JOURNAL OF ANATOMY, 2000, 196 :519-525
[5]  
Fahn S, 1998, Adv Neurol, V78, P1
[6]   Deficit of striatal parvalbumin-reactive GABAergic interneurons and decreased basal ganglia output in a genetic rodent model of idiopathic paroxysmal dystonia [J].
Gernert, M ;
Hamann, M ;
Bennay, M ;
Löscher, W ;
Richter, A .
JOURNAL OF NEUROSCIENCE, 2000, 20 (18) :7052-7058
[7]   Age-dependent alterations of striatal calretinin interneuron density in a genetic animal model of primary paroxysmal dystonia [J].
Hamann, M ;
Sander, SE ;
Richter, A .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2005, 64 (09) :776-781
[8]   Striatal increase of extracellular dopamine levels during dystonic episodes in a genetic model of paroxysmal dyskinesia [J].
Hamann, M ;
Richter, A .
NEUROBIOLOGY OF DISEASE, 2004, 16 (01) :78-84
[9]   Effects of striatal injections of GABAA receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia [J].
Hamann, M ;
Richter, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 443 (1-3) :59-70